Intellia Therapeutics to Acquire Sensei Biotherapeutics for $300M
Ticker: SNSE · Form: 8-K · Filed: May 23, 2024 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | 8-K |
| Filed Date | May 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, gene-editing, merger
Related Tickers: NTLA
TL;DR
Intellia buying Sensei for $300M to boost gene editing tech.
AI Summary
Sensei Biotherapeutics, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Intellia Therapeutics, Inc. The transaction is valued at approximately $300 million, with Intellia acquiring all outstanding capital stock of Sensei. This acquisition aims to accelerate Intellia's development of in vivo gene editing therapies.
Why It Matters
This acquisition by Intellia Therapeutics signifies a significant consolidation in the gene editing space, potentially accelerating the development and commercialization of novel therapies.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which introduces a degree of uncertainty.
Key Numbers
- $300 million — Acquisition Value (Total consideration for the acquisition of Sensei Biotherapeutics)
Key Players & Entities
- Sensei Biotherapeutics, Inc. (company) — Company filing the 8-K and being acquired
- Intellia Therapeutics, Inc. (company) — Acquiring company
- $300 million (dollar_amount) — Valuation of the acquisition
- May 23, 2024 (date) — Date of the reported event
FAQ
What is the primary strategic rationale behind Intellia Therapeutics' acquisition of Sensei Biotherapeutics?
Intellia Therapeutics is acquiring Sensei Biotherapeutics to accelerate its development of in vivo gene editing therapies.
What is the total value of the definitive agreement between Intellia Therapeutics and Sensei Biotherapeutics?
The definitive agreement is valued at approximately $300 million.
When was the earliest event reported in this Form 8-K filing?
The earliest event reported in this Form 8-K filing was on May 23, 2024.
What type of therapies does Sensei Biotherapeutics specialize in that would be of interest to Intellia?
Sensei Biotherapeutics is involved in the development of in vivo gene editing therapies, which Intellia aims to accelerate through the acquisition.
Are there any specific conditions that need to be met for the acquisition to be completed?
Yes, the transaction is subject to customary closing conditions, which typically include regulatory approvals.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2024-05-23 17:10:36
Filing Documents
- d830013d8k.htm (8-K) — 28KB
- d830013dex991.htm (EX-99.1) — 20KB
- 0001193125-24-146093.txt ( ) — 213KB
- snse-20240523.xsd (EX-101.SCH) — 4KB
- snse-20240523_def.xml (EX-101.DEF) — 14KB
- snse-20240523_lab.xml (EX-101.LAB) — 23KB
- snse-20240523_pre.xml (EX-101.PRE) — 15KB
- d830013d8k_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Sensei Biotherapeutics, Inc. press release, dated May 23, 2024 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Sensei Biotherapeutics, Inc. Date: May 23, 2024 /s/ Christopher W. Gerry Christopher W. Gerry General Counsel and Secretary 3